SUZHOU, China, May 16, 2018 /PRNewswire/ -- Innovent Biologics (Suzhou) Co. Ltd. (Innovent Biologics) today announced the findings from the ORIENT-1 trial investigating Sintilimab, the company's fully human anti-PD-1 therapy (IBI308), in patients with relapsed/refractory classical Hodgkin...